

Neuron-targeted gene delivery is a promising strategy to treat peripheral neuropathies. Here we propose the use of polymeric nanoparticles based on thiolated trimethyl chitosan (TMCSH) to mediate targeted gene delivery to peripheral neurons upon a peripheral and minimally invasive intramuscular administration. Nanoparticles were grafted with the non-toxic carboxylic fragment of the tetanus neurotoxin (HC) to allow neuron targeting and were explored to deliver a plasmid DNA encoding for the brain-derived neurotrophic factor (BDNF) in a peripheral nerve injury model. The TMCSH-HC/BDNF nanoparticle treatment promoted the release and significant expression of BDNF in neural tissues, which resulted in an enhanced functional recovery after injury as compared to control treatments (vehicle and non-targeted nanoparticles), associated with an improvement in key pro-regenerative events, namely, the increased expression of neurofilament and growth-associated protein GAP-43 in the injured nerves. Moreover, the targeted nanoparticle treatment was correlated with a significantly higher density of myelinated axons in the distal stump of injured nerves, as well as with preservation of unmyelinated axon density as compared with controls and a protective role in injury-denervated muscles, preventing them from denervation. These results highlight the potential of TMCSH-HC nanoparticles as non-viral gene carriers to deliver therapeutic genes into the peripheral neurons and thus, pave the way for their use as an effective therapeutic intervention for peripheral neuropathies. © 2016 Elsevier Ltd
| Engineering controlled terms: | ChitinChitosanGene transferGenesNanoparticlesNeurons |
|---|---|
| Engineering uncontrolled terms | Brain-derived neurotrophic factorsNeuropathiesNeuroprotectionTargeted nanoparticleTrimethyl chitosan |
| Engineering main heading: | Gene therapy |
| EMTREE drug terms: | alpha bungarotoxinbrain derived neurotrophic factormessenger RNAnanoparticleneuromodulinplasmid DNAprotein S 100brain derived neurotrophic factornanocapsule |
| EMTREE medical terms: | adultallodyniaanimal cellanimal experimentanimal modelanimal tissueArticlecomparative studycontrolled studycrush traumademyelinationembryofemalegastrocnemius musclegene targetinggenetic transfectionhistopathologylocomotionmotor nerve conductionmuscle denervationmuscle reinnervationnerve regenerationneuroprotectionnonhumannonmyelinated nerveperipheral nerve injurypHprimary culturepriority journalprotein expressionratremyelinizationSchwann cellsensorimotor functionsurface areasurface chargeyoung adultzeta potentialadministration and dosageanimalBagg albino mousechemistrygene therapygeneticsmousenerve cellpathologyperipheral nerve injuryplasmidprocedurestreatment outcome |
| MeSH: | AnimalsBrain-Derived Neurotrophic FactorFemaleGenetic TherapyMiceMice, Inbred BALB CNanocapsulesNeuronsPeripheral Nerve InjuriesPlasmidsTreatment Outcome |
alpha bungarotoxin, 11032-79-4; brain derived neurotrophic factor, 218441-99-7;
Brain-Derived Neurotrophic Factor; Nanocapsules
Pêgo, A.P.; i3S, Rua Alfredo Allen, 208, Porto, Portugal;
© Copyright 2017 Elsevier B.V., All rights reserved.